Namostat is used for acute pancreatitis and acute exacerbation of chronic pancreatitis. It is also used for hemodialysis, coronary artery bypass surgery, anticoagulation during liver resection, and glomerulonephritis with systemic lupus erythematosus or mixed cryoglobulinemia (Cryoglobulimemia). It is a synthetic serine proteolytic enzyme inhibitor with anticoagulant, anti-plasmin and anti-platelet aggregation effects.

Market Analysis and Insights: Global Nafamostat Mesylate Market
The global Nafamostat Mesylate market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Nafamostat Mesylate Scope and Market Size
The global Nafamostat Mesylate market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nafamostat Mesylate market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
Purity>98%
Purity<98%

Segment by Application
Pharmaceutical intermediates
Chemical Intermediate
Others

The Nafamostat Mesylate market is analysed and market size information is provided by regions (countries). Segment by Application, the Nafamostat Mesylate market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
BOC Sciences
MedChemexpress
APExBIO
AK Scientific
Service Chemical
Carbone Scientific
Hairui Chem
Carbosynth
Watson International
Capot Chem